Hepatitis C virus is not cleared after primary infection in 50-85% of subjects exposed to hepatitis C virus. Anti-viral treatment during the early phase of infection significantly enhances the likelihood of a sustained clearance of hepatitis C virus. Although, a variety of autoimmune-related side effects have been observed during interferon therapy for chronic hepatitis, immuno-mediated adverse reactions have not been reported during treatment of acute hepatitis C. We describe the case of a patient who developed acute hepatitis C virus infection and, while receiving pegylated interferon alpha-2b monotherapy, developed a severe polymyositis. This case illustrates the potential risk of autoimmunity by interferon, also for acute hepatitis, and underlines the importance of a prompt diagnosis and a rapid discontinuation of interferon treatment for an improvement of clinical outcomes. © 2005 Editrice Gastroenterologica Italiana S.r.l.

Venezia, G., Licata, A., Di Marco, V., Craxì, A., & Almasio, P. (2005). Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b. DIGESTIVE AND LIVER DISEASE, 37(11), 882-885 [10.1016/j.dld.2005.06.010].

Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b

LICATA, Anna;Di Marco, V.;CRAXI, Antonio;ALMASIO, Pier Luigi
2005

Abstract

Hepatitis C virus is not cleared after primary infection in 50-85% of subjects exposed to hepatitis C virus. Anti-viral treatment during the early phase of infection significantly enhances the likelihood of a sustained clearance of hepatitis C virus. Although, a variety of autoimmune-related side effects have been observed during interferon therapy for chronic hepatitis, immuno-mediated adverse reactions have not been reported during treatment of acute hepatitis C. We describe the case of a patient who developed acute hepatitis C virus infection and, while receiving pegylated interferon alpha-2b monotherapy, developed a severe polymyositis. This case illustrates the potential risk of autoimmunity by interferon, also for acute hepatitis, and underlines the importance of a prompt diagnosis and a rapid discontinuation of interferon treatment for an improvement of clinical outcomes. © 2005 Editrice Gastroenterologica Italiana S.r.l.
Venezia, G., Licata, A., Di Marco, V., Craxì, A., & Almasio, P. (2005). Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b. DIGESTIVE AND LIVER DISEASE, 37(11), 882-885 [10.1016/j.dld.2005.06.010].
File in questo prodotto:
File Dimensione Formato  
PDF. Venezia 2003.pdf

accesso aperto

Dimensione 173.5 kB
Formato Adobe PDF
173.5 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/143271
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 17
social impact